Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

98 documents · page 1 of 4

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-COA-MINIMUM-/006Draft certificate-of-analysis minimum data standardDr Liesbeth Nyquist-ObioraThe standard should state a pass limit
DRAFT-COA-MINIMUM-/012Draft certificate-of-analysis minimum data standardDr Theodora IngelbrechtThe document should state what a reader ought to do
DRAFT-RP-HPLC-PURI/003Draft standard: determination of chromatographic purity by…Dr Liesbeth AchterbergThe standard should require documented operator competence
DRAFT-RP-HPLC-PURI/004Draft standard: determination of chromatographic purity by…Dr Jolanta UttridgeThe standard should state a pass limit
DRAFT-SEMAGLUTIDE-/004Draft monograph: semaglutide, version 3Dr Leonhard QuennevilleThe document should state what a reader ought to do
DRAFT-SEMAGLUTIDE-/007Draft monograph: semaglutide, version 3Dr Ludmila TollemacheThe monograph should state what the compound costs
DRAFT-TIRZEPATIDE-/014Draft monograph: tirzepatide, version 2Bertrand Ollerenshaw industryThe document should not describe uses outside the approved indication
DRAFT-WEIGHT-REGAI/014Draft synthesis: weight change after discontinuation of an incretin…Dr Odalys Thorsby-NakamuraThe review question is drawn too broadly to be answerable
DRAFT-WEIGHT-REGAI/016Draft synthesis: weight change after discontinuation of an incretin…Dr Liesbeth Nordhagen industryThe document should not describe uses outside the approved indication
DRAFT-GLP1-OBESITY/012Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…Dr Marisol Dunmore-EkpoThe review question is drawn too broadly to be answerable
DRAFT-THYROID-C-CE/003Draft safety review: the rodent thyroid C-cell signal and its human…Dr Vittoria QuintanilhaThe review question is drawn too broadly to be answerable
DRAFT-PEOPLE-REGIS/004Draft policy on the register of members and reviewersDr Vasilisa ImmelmannRecusal should follow automatically from any declared financial interest
DRAFT-STABILITY-ST/014Draft standard: freeze–thaw and in-use stability assessment of…Georgiana ZimmerthalThe document set should be published in translation
DRAFT-INDICATION-S/007Draft indication set and anchor outcomesVittoria YlönenThe document set should be published in translation
DRAFT-MASH-SYNTHES/011Draft synthesis: incretin receptor agonists for metabolic…Bertrand Ollerenshaw industryThe document should not describe uses outside the approved indication
DRAFT-ADOLESCENT-S/009Draft synthesis: incretin receptor agonists in adolescentsDr Lorcan Whitmarsh-ObiThe document should state what a reader ought to do
DRAFT-ANALYTICAL-S/001Draft analytical review: surveys of unregulated peptide supplyDr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indication
DRAFT-METHODOLOGY-/012Draft methodology document, version 4Dr Rurik Haverkamp-DialloThe document set should be published in translation
DRAFT-MELANOCORTIN/005Draft scoping review: melanocortin receptor agonistsDr Ivo QuintanilhaThe review question is drawn too broadly to be answerable
DRAFT-MELANOCORTIN/008Draft scoping review: melanocortin receptor agonistsDr Emiliana OllerenshawThe document set should be published in translation
DRAFT-SEARCH-STRAT/006Draft search-strategy template for the synthesis seriesVittoria YlönenThe document set should be published in translation
DRAFT-PRINT-AND-AR/005Draft print and archival format for Institute documentsKolawole Oppenheimer-AdeAnonymous submissions should be accepted where the respondent risks employment consequences
DRAFT-AMYCRETIN-MO/006Draft monograph: amycretinDr Beatrijs HazelriggThe monograph should state what the compound costs
DRAFT-AMYCRETIN-MO/013Draft monograph: amycretinDr Rurik Haverkamp-DialloThe document set should be published in translation
DRAFT-5-AMINO-1MQ-/004Draft monograph: 5-amino-1MQDr Prosper VercingetorixThe monograph should state what the compound costs
DRAFT-AOD-9604-MON/006Draft monograph: AOD-9604Dr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-CAGRILINTIDE/008Draft monograph: CagrilintideDr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-ECNOGLUTIDE-/003Draft monograph: EcnoglutideDr Prosper VercingetorixThe monograph should state what the compound costs
DRAFT-EXENATIDE-MO/001Draft monograph: ExenatideDr Quentin Gwynne-SarpongThe document set should be published in translation
DRAFT-GHK-CU-MONOG/004Draft monograph: GHK-CuDr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indication

page 1 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.